<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05092815</url>
  </required_header>
  <id_info>
    <org_study_id>HLX208-LCH/ECD201</org_study_id>
    <nct_id>NCT05092815</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of HLX208 in Adult Langerhans Cell Histiocytosis (LCH) and Erdheim-Chester Disease (ECD) With BRAF V600E Mutation</brief_title>
  <official_title>A Single-arm, Open Label, Multicenter Phase II Clinical Study in Rare Diseases to Evaluate Safety, Efficacy and PK of HLX208 for Adult Langerhans Cell Histiocytosis (LCH) and Erdheim-Chester Disease (ECD) With BRAF V600E Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Henlius Biotech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Henlius Biotech</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to assess safety, efficacy and PK in adult Langerhans Cell&#xD;
      Histiocytosis (LCH) and Erdheim-Chester Disease (ECD) given HLX208 (BRAF V600E inhibitor).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 10, 2021</start_date>
  <completion_date type="Anticipated">May 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Objective response rate(assessed by independent review committee (IRC) based on the PERCIST Version 1.0)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AEs</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Incidence and severity of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Objective response rate(assessed by the investigator based on the PERCIST v1.0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Objective response rate(assessed by IRC and the investigator based on the RECIST v1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Disease control rate (assessed by IRC and the investigator as per PERCIST v1.0 and RECIST v1.1 )</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTR</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Time to response(assessed by IRC and the investigator as per PERCIST v1.0 and RECIST v1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>from the first dose until firstly confirmed and recorded disease progression or death (whichever occurs earlier),assessed up to 1 year</time_frame>
    <description>Progression-free survival (PFS) (assessed by IRC and the investigator as per PERCIST v1.0 and RECIST v1.1 )</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>from the date of first dose until the date of death from any cause，assessed up to 1 year</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>from the date of first dose to 85 days</time_frame>
    <description>Maximum Plasma Concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>from the date of first dose to 85 days</time_frame>
    <description>Time of Maximum Plasma Concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>from the date of first dose to 85 days</time_frame>
    <description>Area Under the Curve</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Langerhans Cell Histiocytosis</condition>
  <condition>Erdheim-Chester Disease</condition>
  <condition>LCH</condition>
  <condition>ECD</condition>
  <arm_group>
    <arm_group_label>HLX208</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive HLX208 450mg bid po</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HLX208</intervention_name>
    <description>HLX208 450mg bid po</description>
    <arm_group_label>HLX208</arm_group_label>
    <other_name>BRAF V600E inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Volunteer to participate in the clinical study;&#xD;
&#xD;
          2. Aged ≥ 18 years;&#xD;
&#xD;
          3. Confirmed adult patients with LCH and/or ECD with BRAF V600E mutation;&#xD;
&#xD;
          4. At least one measurable lesion as per PERCIST v1.0;&#xD;
&#xD;
          5. Expected survival time ≥ 3 months;&#xD;
&#xD;
          6. ECOG score 0-2;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous treatment with BRAF inhibitors or MEK inhibitors;&#xD;
&#xD;
          2. A history of other malignancies within two years, except for cured cervical carcinoma&#xD;
             in situ, basal cell carcinoma of the skin, adenocarcinoma in situ of the lung, or&#xD;
             tumors that do not require interventional treatment after radical surgery;&#xD;
&#xD;
          3. Severe active infections requiring systemic anti-infective therapy;&#xD;
&#xD;
          4. Other anti-tumor treatments, such as chemotherapy, targeted therapy, or radiation&#xD;
             therapy (except palliative radiation therapy), may be given during the study period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xinxin Cao, MD</last_name>
    <phone>69155027</phone>
    <email>caoxinxin@pumch.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xinxin Cao, MD</last_name>
      <phone>69155027</phone>
      <email>caoxinxin@pumch.cn</email>
    </contact>
    <investigator>
      <last_name>Jian Li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 24, 2021</study_first_submitted>
  <study_first_submitted_qc>October 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2021</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Histiocytosis, Langerhans-Cell</mesh_term>
    <mesh_term>Histiocytosis</mesh_term>
    <mesh_term>Erdheim-Chester Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

